Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris Hadaschik; Julie N. Graff; David Olmos; Paul N. Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez‐Gitlitz; Géralyn C. Trudel; Byron M. Espina; Youyi Shu; Youn C. Park; Wayne Rackoff; Margaret K. Yu; Eric J. Small

doi:10.1056/nejmoa1715546

Abstract

Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).

Keywords

Prostate cancerCancerMetastasisOncologyMedicineProstateInternal medicine

Affiliated Institutions

Related Publications

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N. , Neeraj Agarwal , Anders Bjartell +17 more

In this trial involving patients with metastatic, castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer wit...

2019 New England Journal of Medicine 1384 citations

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono , Joaquı́n Mateo , Karim Fizazi +17 more

In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role ...

2020 New England Journal of Medicine 2067 citations

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor , Johann S. de Bono , Kim N. +17 more

BACKGROUND: Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic ca...

2021 New England Journal of Medicine 2181 citations

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , Tim Meyer , Ann‐Lii Cheng +19 more

Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than plac...

2018 New England Journal of Medicine 2228 citations

Publication Info

Year: 2018
Type: article
Volume: 378
Issue: 15
Pages: 1408-1418
Citations: 1271
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1271

OpenAlex

Cite This

APA Style

                            
                                
                                    Matthew R. Smith, 
                                
                                    Fred Saad, 
                                
                                    Simon Chowdhury
                                
                                et al.
                            
                            (2018). 
                            Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. 
                            New England Journal of Medicine
                            , 378
                            (15)
                            , 1408-1418.
                            https://doi.org/10.1056/nejmoa1715546
                        

Identifiers

DOI: 10.1056/nejmoa1715546